Management ChangeMay 19, 2026, 07:02 AM
OKYO Pharma Expands Scientific Advisory Board with Dr. Marta Sacchetti
AI Summary
OKYO Pharma Ltd announced the appointment of Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing its global scientific network with premier European specialists. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases and targeted nerve regeneration will be crucial for the company's global clinical development strategy, particularly for neuropathic corneal pain (NCP). The company's investigational therapy, Urcosimod, which has Fast Track designation, has shown positive results in Phase 2 trials for NCP and dry eye disease.
Key Highlights
- OKYO Pharma appointed Marta Sacchetti, MD, PhD, to its Scientific Advisory Board.
- Dr. Sacchetti brings international expertise in ocular inflammatory and degenerative disease.
- Her previous experience includes Global Head of Clinical Development at Dompé Farmaceutici.
- She will help shape global clinical development strategy for neuro-inflammatory corneal diseases.
- Urcosimod received IND for neuropathic corneal pain and Fast Track designation from FDA.
- Urcosimod showed positive Phase 2 data in 18 neuropathic corneal pain patients.
- Urcosimod showed statistical significance in an earlier 240-patient Phase 2 dry eye trial.
Price Impact
More from OKYO